Retatrutide Clinical Evidence Context Retatrutide has the strongest evidence in obesity, with Phase 3 data now available in obesity without diabetes, obesity with knee osteoarthritis, and type 2 diabetes
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus : a 1-year , randomized controlled trial
Other Medications: Certain central nervous system medications used in GH stimulation tests, for example, dopamine agonists (like L-Dopa) or arginine, can affect GH release
Superoxide dismutase 3 suppresses hyaluronic acid fragments mediated skin inflammation by inhibition of toll-like receptor 4 signaling pathway: superoxide dismutase 3 inhibits reactive oxygen species-induced trafficking of toll-like receptor 4 to lipid rafts
We have also addressed the problem of the speculative nature of the paper, which is also discussed below